Status:
COMPLETED
Treatment of Angiotensin Peptide (1-7) for COVID-19
Lead Sponsor:
Kanuni Sultan Suleyman Training and Research Hospital
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. U...
Detailed Description
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. U...
Eligibility Criteria
Inclusion
- accepted to participate with an informed consent
- proven positive COVID-19
Exclusion
- declined to participate
- genetic/chromosomal abnormalities
- any kind of history of previous adverse events with transfusion
- diagnosis of immune deficiency
Key Trial Info
Start Date :
April 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04375124
Start Date
April 25 2020
End Date
September 30 2020
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kanuni Sultan Suleyman Training and Research Hospital
Istanbul, Turkey (Türkiye), 34303